ICH Draft Q3E Guideline on Extractables & Leachables Now Open for Consultation
- Home
- regulatory updates
- ICH Draft Q3E Guideline on Extractables & Leachables Now Open for Consultation
ICH Draft Q3E Guideline on Extractables & Leachables Now Open for Consultation
Regulatory Affairs Pharma & Biotech Toxicology
Wednesday, 13 August 2025
Javier López, Toxicology Expert at QbD Group
Share
\
\
X (Twitter) 
\
\
LinkedIn 
\
\
WhatsApp 
\
\
Copy link 
\
\
Mail
The International Council for Harmonization (ICH) has advanced the long-anticipated Guideline for Extractables and Leachables (Q3E) to Step 2b, initiating the global public consultation phase.
Play
ICH Draft Q3E Guideline on Extractables & Leachables Now Open for Consultation
AI-generated audio
2:39
This milestone represents a decisive step toward harmonizing international requirements for the assessment and control of leachables in pharmaceuticals, addressing a critical regulatory gap that has historically led to variability and ambiguity across regions.
Key Regulatory Expectations for Sponsors
Scientific Justification
Applications must include a clear, science-based rationale for conducting E&L studies, supported by product and risk specific considerations.
Holistic Risk Management
The guideline outlines a lifecycle-based approach integrating Risk Assessment, Risk Control, and Risk Review, in alignment with ICH Q9 principles.
Comprehensive Technical Appendices
Six detailed annexes provide guidance on topics such as study types, Analytical Evaluation Threshold (AET) calculations, potency-based classification of leachables, exposure limit derivation, and Class 1 leachable monographs.
Why This Guideline Is a Game-Changer
- Closes a long-standing gap
For the first time, a unified framework will exist for leachable risk assessment across oral, parenteral, ophthalmic, and advanced modalities, including cell and gene therapies
- Strengthens risk-based decision making
By linking chemical characterization with toxicological evaluation, the guideline enables sponsors to focus on leachables that are relevant to patient safety, optimizing resources and timelines.
- Regulatory alignment
Harmonization will reduce redundant testing and conflicting expectations, streamlining global submissions and inspections
Strategic Implications for Industry
- Stakeholders are urged to review and comment on the public draft before the consultation closes at the end of 2025.
- With final adoption anticipated post-2027, organizations should begin aligning internal SOPs, vendor qualification processes, and risk assessment methodologies to Q3E principles.
- Early familiarity with the technical annexes will accelerate study design, supplier negotiations, and toxicological evaluations.
The bottom line
The draft ICH Q3E represents a paradigm shift: moving E&L control from a fragmented, product-type-specific exercise to a globally harmonized, science-driven, lifecycle-based process. For companies, it is both a compliance imperative and a strategic opportunity to enhance efficiency, regulatory confidence, and ultimately patient safety.
Extractables & Leachables Reports that ensure your product’s safety
From risk assessments to toxicological evaluations, our team is here to help with all aspects of extractables and leachables reports, protecting your product quality and patient safety.
Discover more regulatory updates
Previous
Regulatory Affairs
18 Sep 2024
The FDA releases revision of guidance regarding Control of Nitrosamine Impurities in Human Drugs
What’s new?
Regulatory Affairs
2 Jun 2025
Nitrosamines Update EMA/409815/2020 Rev.22
What is new?
Regulatory Affairs
9 Jul 2024
New Update of Appendix 1 of the Nitrosamines Guideline
What’s new? In this update, the Acceptable Intake (AI) values for nitrosamines related to the use...
Regulatory Affairs
14 May 2024
Latest Update on Appendix 1 of the Nitrosamine Guidelines
On 01/05/2024, the European Medicines Agency (EMA) rolled out an update to Appendix 1...
Regulatory Affairs
4 Dec 2025
New Update of Appendix 1 of the Nitrosamines Guideline - EMA/42261/2025/Rev. 11
What's new? This update introduces the Acceptable Intake (AI) values for new nitrosamine drug...
Regulatory Affairs
18 Sep 2024
The FDA releases revision of guidance regarding Control of Nitrosamine Impurities in Human Drugs
What’s new?
Regulatory Affairs
2 Jun 2025
Nitrosamines Update EMA/409815/2020 Rev.22
What is new?
Regulatory Affairs
9 Jul 2024
New Update of Appendix 1 of the Nitrosamines Guideline
What’s new? In this update, the Acceptable Intake (AI) values for nitrosamines related to the use...
Regulatory Affairs
14 May 2024
Latest Update on Appendix 1 of the Nitrosamine Guidelines
On 01/05/2024, the European Medicines Agency (EMA) rolled out an update to Appendix 1...
Regulatory Affairs
4 Dec 2025
New Update of Appendix 1 of the Nitrosamines Guideline - EMA/42261/2025/Rev. 11
What's new? This update introduces the Acceptable Intake (AI) values for new nitrosamine drug...
Regulatory Affairs
18 Sep 2024
The FDA releases revision of guidance regarding Control of Nitrosamine Impurities in Human Drugs
What’s new?
Regulatory Affairs
2 Jun 2025
Nitrosamines Update EMA/409815/2020 Rev.22
What is new?
Next
- 1
- 2
- 3
Stay ahead in life sciences
Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.
Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.
Twitter Widget Iframe